Case Study 2: The Discovery and Development of the Multimodal Acting Antidepressant Vortioxetine

Christoffer Bundgaard, Alan L. Pehrson, Connie Sánchez, Benny Bang-Andersen

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review

3 Scopus citations


Vortioxetine, which was approved by the Food and Drug Administration (FDA) on September 30, 2013, for treatment of major depressive disorder (MDD) originates from the line of research aiming at an enhanced therapeutic effect compared to selective serotonin reuptake inhibitors (SSRIs) through modulation of neuroadaptive feedback mechanisms. This research led to a new class of multimodal acting antidepressants, which act via serotonin transporter (SERT ) inhibition and receptor modulation. This chapter deals with vortioxetine's discovery and development, and the impact that careful attention to engaging specific biological targets in the brain has played in its successful development. In drug discovery, in vitro and in vivo drug metabolism and pharmacokinetic (DMPK) studies play a key role in ensuring that the drug-like properties and the developability potential are in place before the compound is advanced to the clinic.

Original languageEnglish
Title of host publicationBlood-Brain Barrier in Drug Discovery
Subtitle of host publicationOptimizing Brain Exposure of CNS Drugs and Minimizing Brain Side Effects for Peripheral Drugs
Number of pages16
ISBN (Electronic)9781118788523
ISBN (Print)9781118788356
StatePublished - 2 Jan 2015


  • Drug metabolism and pharmacokinetic (DMPK)
  • Food and Drug Administration (FDA)
  • Major depressive disorder (MDD)
  • Multimodal acting antidepressant vortioxetine
  • Selective serotonin reuptake inhibitors (SSRIs)


Dive into the research topics of 'Case Study 2: The Discovery and Development of the Multimodal Acting Antidepressant Vortioxetine'. Together they form a unique fingerprint.

Cite this